Phase 2 Myeloma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been formally diagnosed with multiple myeloma (a type of blood cancer) according to standard international diagnostic guidelines, and who at the time of diagnosis had certain measurable levels of abnormal protein in their blood or bone marrow, along with at least one related complication such as anaemia, kidney problems, high calcium levels, or bone damage visible on scans.
• People whose multiple myeloma is currently measurable through at least one of the following: abnormal plasma cells in the bone marrow, abnormal protein levels in the blood or urine, abnormal protein levels detectable through a blood test called a free light chain test, or a visible lesion on a PET/CT or MRI scan.
• People who are either newly diagnosed with multiple myeloma, or whose multiple myeloma has returned or stopped responding to at least one previous treatment.
• People aged 18 years or older.
• People with a general health and activity level rated at 2 or below on a standard medical scale (meaning they are able to care for themselves but may not be able to do heavy physical work) (confirm with trial site).
• Women who could become pregnant must have a negative pregnancy test before joining the trial.
• Women who could become pregnant, and men, must agree to use effective contraception starting 24 hours before and continuing for 24 hours after each scan using the study's imaging agent.
• People who are able to understand the trial and are willing to sign a written consent form.

Who may not be able to join:

• People who have had an allergic reaction to a compound chemically or biologically similar to the standard imaging agent 18F-FDG (used in PET scans).
• People who have had an allergic reaction to a compound chemically or biologically similar to 18F-fluciclovine (the imaging agent used in this trial) or related substances.
• People with severe claustrophobia (fear of enclosed spaces) that does not respond to oral anti-anxiety medication, or who are unwilling to take such medication.
• People with uncontrolled ongoing illness, including mental health conditions or personal circumstances, that would make it difficult to follow the trial requirements.
• People who are currently breastfeeding, as the trial's imaging agent 18F-fluciclovine may pose an unknown risk to nursing infants (breastfeeding would need to be paused for at least 3 days after receiving the imaging agent).

Important: Always verify eligibility with the trial site directly before applying.